Notice of Allowability	Application No.	Applicant(s)
	09/908,955	SAKSENA ET AL.
	Examiner	Art Unit
	Robert B. Mondesi	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. 🔀 This communication is responsive to <u>May 23, 2005</u> .		
2. X The allowed claim(s) is/are <u>39-49 and 51-103</u> .		
3. The drawings filed on are accepted by the Examiner.		
4.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Dat 98), 7. ☑ Examiner's Amendr	te l

EXAMINER'S AMENDMENT

Petition

Petition filed December 11, 2003 under 37 CFR 1.78(a) (6) to accept unintentionally delayed priority claim under 35 USC 119(e) was granted on September 02,2004

Priority

The current application filed on July 19, 2001 claims priority to provisional application 60/220,108 filed on July 21, 2000.

Information Disclosure Statement

The IDS filed May 23, 2005 has been received and is signed and considered, a copy of the PTO 1449 is attached to the following document.

Reasons for allowance

The following is a statement of reasons for the indication of allowable subject matter: Claims 39-44 and 51-64, 66-89 are drawn to specific compounds exhibiting hepatitis C virus protease inhibitory activity and pharmaceutical compositions comprising the mentioned compounds, the prior art which includes the cited references in the IDS filed May 23, 2005 does not teach or suggest the claimed HVC protease inhibitory compounds and pharmaceutical compositions.

Claims 45-49, 65 and 90-103 are drawn to process of using the patentable product; contain the limitations of the allowable product and the prior art, which includes the cited references in the IDS filed May 23, 2005, does not teach or suggest the

Application/Control Number: 09/908,955

Art Unit: 1653

claimed process of using the HVC protease inhibitory compounds and pharmaceutical compositions.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B. Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert B. Mondesi

Rubert B. Man - 08-05-05

JON WEBER SUPERVISORY PATENT EXAMINER

Page 3